{"transactions":[{"id":805725,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev & Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-04-17T20:15:03.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the option vest on April 13, 2027 and 1/48th vest monthly thereafter."}],"balance_after":800000,"derivative":{"exercise_price":1.68,"expiration_date":"2036-04-15","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001193125-26-161558","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526161558/ownership.xml","form_type":"4"}},{"id":810384,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. & Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-10T20:33:56.000Z","date":"2026-04-08","kind":"exercise","planned":true,"acquired":false,"shares":19336,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option is exercisable as follows: 1/48th of the shares subject to the option vest monthly measured from the vesting commencement date of March 1, 2023, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":65977,"derivative":{"exercise_price":19.64,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":19336},"source":{"system":"sec-edgar","filing":"0001628280-26-024716","document":"wk-form4_1775853233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026024716/wk-form4_1775853233.xml","form_type":"4"}},{"id":810383,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. & Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-10T20:33:56.000Z","date":"2026-04-08","kind":"exercise","planned":true,"acquired":false,"shares":9624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option vested monthly measured from the vesting commencement date of February 28, 2022."}],"balance_after":10589,"derivative":{"exercise_price":20.02,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":9624},"source":{"system":"sec-edgar","filing":"0001628280-26-024716","document":"wk-form4_1775853233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026024716/wk-form4_1775853233.xml","form_type":"4"}},{"id":810382,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. & Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-10T20:33:56.000Z","date":"2026-04-08","kind":"exercise","planned":true,"acquired":false,"shares":49474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vested on August 30, 2022, and the remaining number of shares subject to the option vested monthly thereafter in thirty-six equal installments."}],"balance_after":63027,"derivative":{"exercise_price":23.98,"expiration_date":"2031-09-01","underlying":"Common Stock","underlying_shares":49474},"source":{"system":"sec-edgar","filing":"0001628280-26-024716","document":"wk-form4_1775853233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026024716/wk-form4_1775853233.xml","form_type":"4"}},{"id":810381,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. & Operating Officer"}}],"security":"Common Stock","published_at":"2026-04-10T20:33:56.000Z","date":"2026-04-08","kind":"sale","planned":true,"acquired":false,"shares":85163,"price":40.1,"value":3415036.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on  December 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $40.10 per share. The range of sale prices on\nthe transaction date was $40.00 to $40.34. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":105289,"source":{"system":"sec-edgar","filing":"0001628280-26-024716","document":"wk-form4_1775853233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026024716/wk-form4_1775853233.xml","form_type":"4"}},{"id":810380,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. & Operating Officer"}}],"security":"Common Stock","published_at":"2026-04-10T20:33:56.000Z","date":"2026-04-08","kind":"exercise","planned":true,"acquired":true,"shares":19336,"price":19.64,"value":379759.04,"ownership":{"direct":true},"balance_after":190452,"source":{"system":"sec-edgar","filing":"0001628280-26-024716","document":"wk-form4_1775853233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026024716/wk-form4_1775853233.xml","form_type":"4"}},{"id":810379,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. & Operating Officer"}}],"security":"Common Stock","published_at":"2026-04-10T20:33:56.000Z","date":"2026-04-08","kind":"exercise","planned":true,"acquired":true,"shares":9624,"price":20.02,"value":192672.48,"ownership":{"direct":true},"balance_after":171116,"source":{"system":"sec-edgar","filing":"0001628280-26-024716","document":"wk-form4_1775853233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026024716/wk-form4_1775853233.xml","form_type":"4"}},{"id":810378,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. & Operating Officer"}}],"security":"Common Stock","published_at":"2026-04-10T20:33:56.000Z","date":"2026-04-08","kind":"exercise","planned":true,"acquired":true,"shares":49474,"price":23.98,"value":1186386.52,"ownership":{"direct":true},"balance_after":161492,"source":{"system":"sec-edgar","filing":"0001628280-26-024716","document":"wk-form4_1775853233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026024716/wk-form4_1775853233.xml","form_type":"4"}},{"id":834983,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-18T21:13:24.000Z","date":"2026-03-16","kind":"sale","planned":true,"acquired":false,"shares":3961,"price":37.77,"value":149606.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, March 4, 2024, and February 20, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":112018,"source":{"system":"sec-edgar","filing":"0001628280-26-019503","document":"wk-form4_1773868401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026019503/wk-form4_1773868401.xml","form_type":"4"}},{"id":834982,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-18T21:13:24.000Z","date":"2026-03-16","kind":"sale","planned":true,"acquired":false,"shares":5950,"price":37.11,"value":220804.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, March 4, 2024, and February 20, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":115979,"source":{"system":"sec-edgar","filing":"0001628280-26-019503","document":"wk-form4_1773868401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026019503/wk-form4_1773868401.xml","form_type":"4"}},{"id":881975,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-25T21:34:51.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026."}],"balance_after":55000,"derivative":{"exercise_price":43.79,"expiration_date":"2036-02-23","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001628280-26-011723","document":"wk-form4_1772055288.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026011723/wk-form4_1772055288.xml","form_type":"4"}},{"id":881974,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-25T21:34:51.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 438 shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":121929,"source":{"system":"sec-edgar","filing":"0001628280-26-011723","document":"wk-form4_1772055288.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026011723/wk-form4_1772055288.xml","form_type":"4"}},{"id":1194622,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-03-21T22:33:31.000Z","date":"2025-03-19","kind":"sale","planned":true,"acquired":false,"shares":361,"price":34.83,"value":12573.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.83 per share. The range of sales prices on the transaction date was $34.78 to $35.00 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":87491,"source":{"system":"sec-edgar","filing":"0000950170-25-043404","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025043404/ownership.xml","form_type":"4"}},{"id":1194621,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-03-21T22:33:31.000Z","date":"2025-03-19","kind":"sale","planned":true,"acquired":false,"shares":6801,"price":34.17,"value":232390.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.17 per share. The range of sales prices on the transaction date was $33.78 to $34.77 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":87852,"source":{"system":"sec-edgar","filing":"0000950170-25-043404","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025043404/ownership.xml","form_type":"4"}},{"id":1249525,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-24T21:30:09.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 20, 2025."}],"balance_after":65000,"derivative":{"exercise_price":36.86,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000950170-25-025666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025025666/ownership.xml","form_type":"4"}},{"id":1249524,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-02-24T21:30:09.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":43000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2026."}],"balance_after":94653,"source":{"system":"sec-edgar","filing":"0000950170-25-025666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025025666/ownership.xml","form_type":"4"}},{"id":1350919,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-11-26T21:30:09.000Z","date":"2024-11-22","kind":"sale","planned":true,"acquired":false,"shares":501,"price":56.52,"value":28316.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 501 shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":51653,"source":{"system":"sec-edgar","filing":"0000950170-24-131064","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024131064/ownership.xml","form_type":"4"}},{"id":1452581,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (Right to Buy)","published_at":"2024-07-17T21:35:34.000Z","date":"2024-07-15","kind":"exercise","planned":true,"acquired":false,"shares":5687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option vested on April 1, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":85313,"derivative":{"exercise_price":19.64,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":5687},"source":{"system":"sec-edgar","filing":"0000950170-24-084346","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024084346/ownership.xml","form_type":"4"}},{"id":1452580,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (Right to Buy)","published_at":"2024-07-17T21:35:34.000Z","date":"2024-07-15","kind":"exercise","planned":true,"acquired":false,"shares":2887,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":20213,"derivative":{"exercise_price":20.02,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":2887},"source":{"system":"sec-edgar","filing":"0000950170-24-084346","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024084346/ownership.xml","form_type":"4"}},{"id":1452579,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (Right to Buy)","published_at":"2024-07-17T21:35:34.000Z","date":"2024-07-15","kind":"exercise","planned":true,"acquired":false,"shares":17499,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":112501,"derivative":{"exercise_price":23.98,"expiration_date":"2031-09-01","underlying":"Common Stock","underlying_shares":17499},"source":{"system":"sec-edgar","filing":"0000950170-24-084346","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024084346/ownership.xml","form_type":"4"}},{"id":1452578,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-07-17T21:35:34.000Z","date":"2024-07-15","kind":"sale","planned":true,"acquired":false,"shares":27000,"price":55,"value":1485000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":51653,"source":{"system":"sec-edgar","filing":"0000950170-24-084346","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024084346/ownership.xml","form_type":"4"}},{"id":1452577,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-07-17T21:35:34.000Z","date":"2024-07-15","kind":"exercise","planned":true,"acquired":true,"shares":5687,"price":19.64,"value":111692.68,"ownership":{"direct":true},"balance_after":78653,"source":{"system":"sec-edgar","filing":"0000950170-24-084346","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024084346/ownership.xml","form_type":"4"}},{"id":1452576,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-07-17T21:35:34.000Z","date":"2024-07-15","kind":"exercise","planned":true,"acquired":true,"shares":2887,"price":20.02,"value":57797.74,"ownership":{"direct":true},"balance_after":72966,"source":{"system":"sec-edgar","filing":"0000950170-24-084346","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024084346/ownership.xml","form_type":"4"}},{"id":1452575,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-07-17T21:35:34.000Z","date":"2024-07-15","kind":"exercise","planned":true,"acquired":true,"shares":17499,"price":23.98,"value":419626.02,"ownership":{"direct":true},"balance_after":70079,"source":{"system":"sec-edgar","filing":"0000950170-24-084346","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024084346/ownership.xml","form_type":"4"}},{"id":1467188,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-06-28T21:31:49.000Z","date":"2024-06-26","kind":"sale","planned":true,"acquired":false,"shares":956,"price":44.38,"value":42427.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 956 shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":52580,"source":{"system":"sec-edgar","filing":"0000950170-24-079152","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024079152/ownership.xml","form_type":"4"}},{"id":1560568,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-26T20:30:42.000Z","date":"2024-03-22","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":130000,"derivative":{"exercise_price":23.98,"expiration_date":"2031-09-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-24-005081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005081/doc4.xml","form_type":"4"}},{"id":1560567,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-03-26T20:30:42.000Z","date":"2024-03-22","kind":"sale","planned":false,"acquired":false,"shares":2359,"price":45.39,"value":107075.01,"ownership":{"direct":true},"balance_after":52580,"source":{"system":"sec-edgar","filing":"0001209191-24-005081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005081/doc4.xml","form_type":"4"}},{"id":1560566,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-03-26T20:30:42.000Z","date":"2024-03-22","kind":"sale","planned":false,"acquired":false,"shares":30000,"price":44.22,"value":1326600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.22 per share. The range of sales prices on the transaction date was $44.00 to $44.52 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":54939,"source":{"system":"sec-edgar","filing":"0001209191-24-005081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005081/doc4.xml","form_type":"4"}},{"id":1560565,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-03-26T20:30:42.000Z","date":"2024-03-22","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":23.98,"value":719400.0,"ownership":{"direct":true},"balance_after":84939,"source":{"system":"sec-edgar","filing":"0001209191-24-005081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005081/doc4.xml","form_type":"4"}},{"id":1565952,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-03-20T22:35:34.000Z","date":"2024-03-18","kind":"tax_withholding","planned":true,"acquired":false,"shares":4283,"price":38.14,"value":163353.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022 and March 1, 2023.  The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":54939,"source":{"system":"sec-edgar","filing":"0001209191-24-005012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005012/doc4.xml","form_type":"4"}},{"id":1591626,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-07T00:59:29.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":87000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 4, 2024."}],"balance_after":87000,"derivative":{"exercise_price":43.51,"expiration_date":"2034-03-03","underlying":"Common Stock","underlying_shares":87000},"source":{"system":"sec-edgar","filing":"0001209191-24-004606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124004606/doc4.xml","form_type":"4"}},{"id":1591625,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-03-07T00:59:29.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025."}],"balance_after":59222,"source":{"system":"sec-edgar","filing":"0001209191-24-004606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124004606/doc4.xml","form_type":"4"}},{"id":1649207,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-02-12T21:32:37.000Z","date":"2023-11-20","kind":"other","planned":false,"acquired":true,"shares":931,"price":14.98,"value":13946.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),"}],"balance_after":36222,"source":{"system":"sec-edgar","filing":"0001209191-24-003095","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124003095/doc5.xml","form_type":"5"}},{"id":1649206,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-02-12T21:32:37.000Z","date":"2023-05-22","kind":"other","planned":false,"acquired":true,"shares":891,"price":14.98,"value":13347.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),"}],"balance_after":35291,"source":{"system":"sec-edgar","filing":"0001209191-24-003095","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124003095/doc5.xml","form_type":"5"}},{"id":1946998,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-03-17T21:08:29.000Z","date":"2023-03-16","kind":"tax_withholding","acquired":false,"shares":587,"price":17.12,"value":10049.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022.  The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":34400,"source":{"system":"sec-edgar","filing":"0001209191-23-019768","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919123019768/doc4.xml","form_type":"4"}},{"id":1973499,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-03T21:35:15.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":91000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 1, 2023."}],"balance_after":91000,"derivative":{"exercise_price":19.64,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":91000},"source":{"system":"sec-edgar","filing":"0001209191-23-015556","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919123015556/doc4.xml","form_type":"4"}},{"id":1973498,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-03-03T21:35:15.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2024."}],"balance_after":34987,"source":{"system":"sec-edgar","filing":"0001209191-23-015556","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919123015556/doc4.xml","form_type":"4"}},{"id":2043706,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-01-27T21:27:37.000Z","date":"2022-11-20","kind":"other","acquired":true,"shares":537,"price":15.16,"value":8140.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),"}],"balance_after":5487,"source":{"system":"sec-edgar","filing":"0001209191-23-005253","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919123005253/doc5.xml","form_type":"5"}},{"id":2200222,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-07-29T20:26:53.000Z","date":"2022-07-26","kind":"sale","acquired":false,"shares":1152,"price":20.7004,"value":23846.8608,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales\nprice of $20.7004 per share. The range of actual sales prices on the transaction date was $20.69 to $20.7016 per share. Detailed information on\nthe exact number of shares sold at each price can be obtained from the issuer upon request."}],"balance_after":4950,"source":{"system":"sec-edgar","filing":"0001209191-22-043524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919122043524/doc4.xml","form_type":"4"}},{"id":2200221,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-07-29T20:26:53.000Z","date":"2022-05-20","kind":"other","acquired":true,"shares":1152,"price":17.44,"value":20090.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b)\npursuant to Rule 16b-3(c)."}],"balance_after":6102,"source":{"system":"sec-edgar","filing":"0001209191-22-043524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919122043524/doc4.xml","form_type":"4"}},{"id":2360749,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-03T02:00:47.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":23100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022."}],"balance_after":23100,"derivative":{"exercise_price":20.02,"expiration_date":"2032-02-27","underlying":"Common Stock","underlying_shares":23100},"source":{"system":"sec-edgar","filing":"0001209191-22-015133","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919122015133/doc4.xml","form_type":"4"}},{"id":2360748,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-03-03T02:00:47.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":4950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023."}],"balance_after":4950,"source":{"system":"sec-edgar","filing":"0001209191-22-015133","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919122015133/doc4.xml","form_type":"4"}},{"id":2581652,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":52060,"kind":"person","name":"Knight Jeff E.","position":1,"cik":"0001881007","reported_name":"Knight Jeff E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-02T21:05:17.000Z","date":"2021-09-01","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":160000,"derivative":{"exercise_price":23.98,"expiration_date":"2031-08-30","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-21-054490","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121054490/doc4.xml","form_type":"4"}}]}